Royalty Pharma plc (RPRX): Valuation
TTM figures as of June 30, 2026
Royalty Pharma plc trades at 32.0 times trailing earnings. On P/E that is higher than 59% of its own month-end history back to 2020. The Healthcare median P/E is 22.9.
Earnings yield 3.12%. Shareholder yield 1.23%. ROIC 8.4%. Net debt $8.1B.
75 month-end valuation observations are on file, starting June 2020.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is RPRX cheap versus its own history?
Royalty Pharma plc trades at 32.0 times trailing earnings. On P/E that is higher than 59% of its own month-end history back to 2020. The Healthcare median P/E is 22.9.
What is RPRX's free-cash-flow yield?
Free-cash-flow yield is trailing free cash flow divided by the live market cap. It is omitted when free cash flow is missing.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.